Breakthrough Infections with SARS-CoV-2 Omicron Variant Despite Booster Dose of mRNA Vaccine
8 Pages Posted: 10 Dec 2021 Last revised: 21 Jan 2022
Date Written: December 9, 2021
Based on its genetic profile and preliminary in vitro and epidemiological data, the recently emerged SARS-CoV-2 Omicron variant is predicted to evade immune responses to some extent. We report a cluster of Omicron variant infections in individuals who had received full primary vaccination series and booster doses with mRNA vaccines. All patients experienced symptomatic COVID-19 but clinical manifestations were mild to moderate. Their SARS-CoV-2 viral RNA loads and anti-spike antibody levels were determined. This series proves that even three doses of mRNA vaccines may not be sufficient to prevent infection and symptomatic disease with the Omicron variant.
Funding Information: Funding was provided by South African Medical Research Council, Poliomyelitis Research Foundation and National Health Laboratory Service Research Trust
Conflict of Interests: Wolfgang Preiser serves as member of the South African Ministerial Advisory Committee on COVID-19 Vaccines. All other others declare no conflict of interests.
Ethical Approval: The investigation was approved by the Health Research Ethics Committee of Stellenbosch University (REFERENCE NUMBER TO BE INSERTED ONCE AVAILABLE) and all participants provided informed consent.
Keywords: SARS-CoV-2, Omicron variant, B.1.1.529, vaccine breakthrough infection, booster vaccination, COVID-19, mRNA vaccine
Suggested Citation: Suggested Citation